PDCD1 and neoplasm: These monoclonal antibodies (mAbs) specifically target inhibitory proteins, including cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed cell death protein-1 (PD-1), and programmed death-ligand 1 (PD-L1), thereby augmenting T-cell activation and anti-tumor immunity [3].